Наукові праці. Кафедра онкології
Permanent URI for this collectionhttps://repo.knmu.edu.ua/handle/123456789/1546
Browse
11 results
Search Results
Item The lncRNA BORG abnormal expression in Advanced Breast Cancer Chemoresistant and Recurrence(2024-12-03) Muzhychuk, Oleksii; Starikov, Volodymyr; Lykhman, Viktor; Sennikov, Ihor; Yevtushenko, Dmytro; Khodak, Andrii; Kotenko, Oleksandr; Gavrilov, AndriiBackground. Multiple molecular alterations are observed in breast cancer. Among the functions attributed to lncRNA-BORG are various carcinogenic processes that function during the formation chemoresistant and recurrence of primary tumors. In this study, we aimed to identify lncRNA BORG expression signature, that can predict breast cancer patient recurrence-free survival.Purpose – evaluate long non-coding RNA expression as diagnostic marker for disease prognosis and prediction of treatment effect.Materials and Methods. A total of 40 advanced resistant breast cancer patients were divided into two groups: 1) Basal and Luminal B HER-2 positive (n = 20); 2) Luminal A (n = 20), were obtained with overall survival compared with relapse-free status patients.The bioinformatics prediction is confirmed by polymerase chain reaction (PCR). To investigate the prognostic accuracy of multi-lncRNA BORG-based classifier, time-dependent receiver operating characteristic analysis was performed using the ‘survival ROC’ R package. Relapse-free survival was analyzed based on Kaplan–Meier method, and the log-rank test was performed to assess the statistical significance of the differences.Results. High lncRNA BORG protein expression was shown to have the highest correlation with positive hormone status (OR = 2.79; 95% confidence interval (95% CI), 1.27 – 4.20). Furthermore, HER2 overexpression (OR = 1.65; 95% CI, 1.26 – 2.13) was linked to important hormone status. Patients with HER2 positive/lncRNA BORG present high expression had a fourfold increased risk of relevant hormone status compared to patients with HER2 negative/lncRNA BORG show low expression, and an estimated 16.4% cumulative risk of recurrence developing relevant at two years. We discovered a predictive function for lncRNA BORG for identification, which has the potential to enhance clinical care of women with Advanced Breast Cancer (ABC). High HER2-positive/lncRNA BORG expression was linked to ER-negative disease recurrences. Our findings highlight the necessity of assessing protein expression of HER2 and lncRNA BORG to evaluate the probability of disease recurrence in ABC patients following diagnosis and therapy. Patients with low lncRNA BORG expression had a recurrence risk that is equivalent to the general population.Conclusions. We discovered a predictive function for lncRNA BORG for identification, which has the potential to enhance clinical care of women with ABC.Women with HER2-positive/lncRNA BORG high expression lesions had a fourfold greater frequency of subsequent hormone status than women with HER2-negative/lncRNA BORG low expression lesions.High HER2-positive/lncRNA BORG expression was linked to ER-negative disease chemoresistance and recurrence. Our findings highlight the necessity of assessing protein expression of HER2 and lncRNA BORG to evaluate the probability of disease recurrence in ABC patients following diagnosis and therapy.Patients with low lncRNA BORG expression had chemoresistance and a high recurrence risk that is equivalent to the general population.Item Study of phe-nolic compounds of umbellate wintergreen herb and their influence on biochemical indicators of blood and urine in the rat model of chronickidney disease(2024-08-30) Kovregin, Oleksiy; Lytkin, Dmytro; Mykhailenko, Olha; Ivanauskas, Liudas; Yudkevych, Tetiana; Vladymyrova, Inna; Khodak, Larisa; Starikov, VolodymyrItem Аrtificial intelligence in oncology, is it time to include its study in the course «Оncology and medical radiology»(2024) Baranova, Anna; Havrylov, Andrii; Kotenco, Olexander; Muzhychuk, Olexii; Sennikov, IhorItem Morphological and immunohistochemical prognostic criteria for small cell lung cancers(2024) Yakovtsova, Iryna; Starikov, Volodymyr; Ivakhno, Ihor; Yanchevskyi, Oleksandr; Abdullaieva, Anhelina; Mirzebasov, MaksymItem Experimental study of receptor antagonist interleukin-1 cerebroprotective properties(2021-12) Старіков, Володимир Іванович; Щокіна, Катерина Геннадіївна; Дроговоз, Світлана Мефодіївна; Shchokina, K.; Drogovoz, S.; Kalko, K.; Starikov, V.In modern conditions craniocerebral trauma (ССT) is one of the most common pathologies. The search for new means of correcting ССT is an urgent task of medicine and pharmacy. According to the modern concept, the pathogenesis of brain lesions involves an increase in the production of proinflammatory cytokines, including interleukin-1. Attracts attention of the possibility to solve this problem by blockade of receptors of interleukin-1 (IL-1). The aim of this study was to evaluate the effectiveness of raleukin in traumatic CNS lesions in a model of traumatic brain injury in rats. Materials and methods. Raleukin injected at a dose of 15 mg / kg subcutaneously, referent-drug Piracetam (200 mg / kg) intraperitoneally 30 minutes before the modeling of CCT. Closed trauma of moderate severity was simulated under light etheric anesthesia (immediately after the lateral position of the animal) by the method of dosed impact on the parieto-occipital region with a weight of 0.0495 kg with an energy of 0.315 J in a special device. Immediately after the application of CCT determined the time of recovery of motor activity of animals. After 24 hours, the open field and rotating rod tests were repeated. This allowed us to assess the dynamics of the CNS. The main results. In the article are the results of studies of the effect of recombinant human receptor antagonist of interleukin-1 (Raleukin) status of animals after closed craniocerebral trauma. Found that Raleukin more effective of piracetam restores motor activity of animals in the acute period of experimental BI. Against the background of Raleukin recovery in the functional state of central nervous system (muscle tone and motor coordination, motor and research activity, emotional reaction) in craniocerebral trauma rehabilitation period is better than under the influence of piracetam.Item Experience and prospects for the use of off-label drugs in oncology(2021-03-25) Старіков, Володимир Іванович; Дроговоз, Світлана Мефодіївна; Іванцик, Леся Богданівна; Щокіна, Катерина Геннадіївна; Drogovoz, S.; Starikov, V.; Ivantsyk, L.; Shchokina, K.Summary. According to the World Health Organization, half of all drugs available on the global pharmaceutical market are sometimes used for indications that are not included in the instruction for use. This method of therapy has the term “off-label use” which means the use “out of instruction”. Today, off-label drugs are also prescribed for cancer treatment. For example, a drug developed to treat one type of tumor can sometimes be used to treat other types of cancer. The treatment of certain types of pain with tricyclic antidepressants is also an example of the off-label drugs used in oncology. An example of an off-label prescription is anxiolytic medicine lorazepam, which can be used off-label as an antiemetic in cancer patients. Low doses of naltrexone are applied to treat cancer and autoimmune diseases. A retrospective analysis of modern oncotherapy indicates that oncologists often use off-label drugs in combination therapy, especially in the treatment of patients with concomitant diseases, in case of progressive development of the tumor, or to reduce the toxicity and cost of treatment components. American oncologists are of the opinion that if all the drugs prescribed by the International Recommendations failed in the treatment of cancer, doctors can prescribe off-label medications, but only if their effectiveness and safety are clearly established. The problem of the off-label use of drugs in oncology has not yet been studied in detail, however, this direction has certain promising prospects.Item Organ-saving and reconstructive plastic surgery of breast cancer(2020) Tamm, T.; Vinnyk, Yu.; Starikov, V.; Prokopyuk, O.; Oleynik, G.; Vlasenko, V.Item Oncolytic viruses as immunotherapeutic agents(Tehran University of Medical Sciences, 2020-09-25) Havrilov, Andrii; Trehub, YevheniiItem Prognostic value of individual tumor cells in bone marrow, lymph nodes in patients with non-small cell lung carcinoma(2017) Starikov, Vladimir; Makarov, Vitalii; Syrovaya, Anna; Khodak, Andrei; Zavada, OksanaThe results of the examination of the bone marrow and distant lymph nodes for the presence of circulating tumor cells in 83 patients with non-small cell lung cancer T2-3N0M0, who had been radically operated, are given. Isolated tumor cells were determined by immune cytochemical and immune histochemical methods with the monoclonal antibodies to cytokeratins. Isolated tumor cells were detected in bone marrow in 30.1% and in lymph nodes in 20.5% of patients. The simultaneous presence of isolated tumor cells in bone marrow and lymph nodes was found in 18.1% of patients that significantly reduced the 3-year survival rate. Isolated tumor cells can be considered as a negative prognostic factor that must be taken into account when choosing the adjuvant treatment of lung carcinoma.Item Thyroid cancer and background thyroid parenchyma patterns, a 29 years study(2014) Muzhichuk, Alexei; Bodjre, Kouame Eloi Frejus